Maximum Reduction. The maximum aggregate reduction with respect to each applicable Licensed Product during any Calendar Quarter pursuant to this Section 3.4(f) shall be capped at [***] of the amount of the royalty that would be payable under Section 3.4(a) prior to any such reductions.
Appears in 1 contract
Sources: License Agreement (Lipocine Inc.)
Maximum Reduction. The maximum aggregate reduction with respect to each applicable Licensed any Product in any country during any Calendar Quarter pursuant to this Section 3.4(f7.5.4 and Section 7.5.5 (alone or in combination) shall be capped at [***] of the amount of the royalty that would be payable in respect of Net Sales in such country under Section 3.4(a) 7.5.3, prior to any such reductions.
Appears in 1 contract
Sources: Collaboration and License Agreement (CytomX Therapeutics, Inc.)
Maximum Reduction. The maximum aggregate reduction with respect to each applicable any Licensed Product in any country during any Calendar Quarter pursuant to this Section 3.4(f) 7.4.4 shall be capped at [***] of the amount of the royalty that would be payable in respect of Net Sales in such country under Section 3.4(a) 7.4.3, prior to any such reductions, and any unused portions of the reduction shall be carried-forward in future Calendar Quarters.
Appears in 1 contract
Sources: Collaboration and License Agreement (CytomX Therapeutics, Inc.)
Maximum Reduction. The maximum aggregate reduction with respect to each applicable Licensed any Product in any country during any Calendar Quarter pursuant to this Section 3.4(f7.4.4(a) and Section 7.4.5 (alone or in combination) shall be capped at [***] of the amount of the royalty Royalties that would be payable in respect of Net Sales in such country under Section 3.4(a) 7.4.3, prior to any such reductions.
Appears in 1 contract
Sources: Collaboration and License Agreement (Aerie Pharmaceuticals Inc)
Maximum Reduction. The maximum aggregate reduction with respect to each applicable any Licensed Product in any country during any Calendar Quarter pursuant to this Section 3.4(f7.5.4 (Royalty Reductions) (alone or in combination) shall be capped at [***] of the amount of the royalty that would be payable in respect of Net Sales in such country under Section 3.4(a) 7.5.3 (Royalty Rates), prior to any such reductions; [***].
Appears in 1 contract
Sources: Collaboration and License Agreement (CytomX Therapeutics, Inc.)